CD14 and rheumatoid arthritis: Nevertheless, in addition to the description of a new mechanism in the pathology of RA, the role of monocyte–PLT conjugates in the modulation of inflammation, our results suggest that the percentage of CD14+PLT+ can be applied as a biomarker of early remission to TCZ treatment.